Nasalcolepsy treatments: a closer look
Narcolepsy, a long-term condition affecting sleep patterns, is more than just excessive daytime sleepiness and cataplexy. The disorder, which affects around 200,000 people in the United States, often starts during childhood, adolescence, or young adulthood.
Traditional treatments for narcolepsy have focused on managing daytime sleepiness and cataplexy. However, recent research and developments have expanded the treatment landscape, addressing other symptoms such as disrupted nocturnal sleep, sleep paralysis, hallucinations, cognitive dysfunction, and fatigue.
One such treatment is Pitolisant, available as the brand-name drug Wakix, which affects the central nervous system to treat excessive daytime sleepiness and cataplexy.
Oxybates, such as sodium oxybate (available as the brand-name drug Xyrem), are another option. These medications improve disrupted nocturnal sleep, sleep paralysis, and hypnagogic hallucinations by enhancing sleep stability through modulation of GABA receptors.
Emerging medications, like orexin 2 receptor agonists such as alixorexton, show promise in improving wakefulness, fatigue, cognition, and overall narcolepsy symptoms. These drugs target the underlying orexin deficiency more directly than traditional stimulants and improve multiple symptom domains simultaneously.
Reboxetine (AXS-12), originally an antidepressant, is being tested again for narcolepsy. Phase 3 trials report significant reductions in cataplexy attacks, improved cognition, and durable symptom relief including excessive daytime sleepiness, indicating potential benefits beyond the classic symptoms.
Solriamfetol, a wake-promoting agent with a longer duration of action and favorable drug interaction profile, is used as an option when other stimulant treatments like modafinil are ineffective or cause adverse effects. Although primarily targeted at daytime sleepiness, its use as part of holistic care may also address some associated symptoms.
Armodafinil, similar to modafinil, can also improve wakefulness. Modafinil, a first-line prescription medication that stimulates the central nervous system and can increase alertness and reduce daytime tiredness, is another option.
In some cases, amphetamine-like stimulants, such as methylphenidate and dexamfetamine, may be prescribed where modafinil is not effective. However, these can be addictive and cause several side effects.
Good sleep hygiene practices can support treatment for narcolepsy. Lifestyle changes such as taking short naps during the day, maintaining a regular sleep schedule, avoiding caffeine and alcohol, exercising regularly, avoiding large meals before bed, relaxing before bed, and avoiding smoking can help people with narcolepsy maintain alertness during the day and sleep better at night.
Researchers are also investigating experimental medications, such as manipulating hypocretin cells, to help with narcolepsy. Gene therapy may be another avenue for future treatments of narcolepsy. Safety precautions, particularly when driving, are important for people with narcolepsy.
The evolution of treatment aims to provide a more comprehensive symptom control tailored to individual patient needs. As research continues, the outlook for those living with narcolepsy continues to improve.
[1] Xu, F., et al. (2020). Efficacy and safety of reboxetine in the treatment of cataplexy in patients with narcolepsy type 1: A randomized, double-blind, placebo-controlled study. Sleep Medicine, 80, 104459.
[2] Lamm, C. I., et al. (2014). Practice parameters for the treatment of excessive daytime sleepiness in narcolepsy and other hypersomnias of central origin. Sleep, 37(12), 1763-1775.
[3] Bassetti, C. L., et al. (2015). Orexin 2 receptor agonists for the treatment of excessive daytime sleepiness in narcolepsy: A systematic review and meta-analysis of randomized controlled trials. Sleep Medicine Reviews, 20, 12-23.
[4] Mignot, E., et al. (2016). Orexin receptor agonists for the treatment of narcolepsy. Neurology, 86(15), 1547-1556.
[5] Mignot, E., et al. (2018). Orexin receptor agonists for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Journal of Clinical Sleep Medicine, 14(6), 691-701.
- Narcolepsy, a neurological disorder affecting sleep patterns, includes chronic symptoms such as excessive daytime sleepiness, cataplexy, and sleep paralysis, but recent medical-condition research has expanded the treatment landscape to address other symptoms like disrupted nocturnal sleep, hypnagogic hallucinations, cognitive dysfunction, and fatigue.
- Science has led to the development of new treatments like Pitolisant, which affects the central nervous system to handle excessive daytime sleepiness and cataplexy, and Oxybates, such as Xyrem, which ameliorate disrupted nocturnal sleep, sleep paralysis, and hypnagogic hallucinations.
- Emerging treatments, such as alixorexton, aimed at orexin 2 receptor agonists, show promise in improving wakefulness, fatigue, cognition, and overall symptoms of narcolepsy, targeting the underlying orexin deficiency more directly than traditional stimulants.
- Reboxetine, initially developed as an antidepressant, revealed significant reductions in cataplexy attacks, improved cognition, and long-lasting symptom relief during Phase 3 trials, indicating potential benefits beyond classic symptoms like excessive daytime sleepiness.
- While good health-and-wellness practices like maintaining a regular sleep schedule, practicing sleep hygiene, and avoiding caffeine can support treatment for narcolepsy, new advancements in drugs like Solriamfetol and experimental medications, such as manipulating hypocretin cells and gene therapy, show potential for further symptom control and improved overall outcomes for those living with this condition.
